A study published Monday in Pediatrics reported a threefold rise in calls to poison centers for attention-deficit/hyperactivity disorder, or ADHD, drug-related adverse events. A particularly sharp increase in calls beginning around 2009 coincides with the approval of guanfacine, marketed under the brand name Tenex.